Could a common bile acid pill shield kidneys during cancer surgery?

NCT ID NCT07672860

Recruiting now Disease control Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take UDCA or a placebo from two days before surgery to five days after. The study measures acute kidney injury rates and kidney function changes, aiming to see if UDCA reduces damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ursodeoxycholic acid (UDCA)
What this could lead to: If it works, UDCA could become a simple, safe way to protect kidney function during kidney cancer surgery, reducing the risk of acute kidney injury.
What could go wrong: This is a small, early-phase trial. UDCA may not provide significant protection, and results may not apply to all patients or surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury ischemia reperfusion injury kidney cancer kidney neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER

Contacts and locations

Locations

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
RECRUITING

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.